Conference Correspondent

Blinatumomab Demonstrates Overall Survival Benefit in Adults with Relapsed ALL in the TOWER Study

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

CD19 CAR T Cells Induce Potent Responses and Control CNS Leukemia in Relapsed ALL

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

CLL – Clinical Poster Session: Friday, June 10

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Duration of TKI Treatment and Duration of Deep Molecular Response Affect Relapse-Free Survival in CML

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Higher-Dose Daunorubicin Is Effective in Patients with AML Who Harbor FLT3-ITD Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Ibrutinib plus Bendamustine and Rituximab (BR) in Previously Treated CLL/SLL: 2-Year Follow-Up Data from the HELIOS Study

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Innovative Therapies in CLL: Saturday, June 11

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Length of Time on Treatment Observed in Ibrutinib Clinical Trials Is Reproducible After Assessment of Real-World Data

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Outcomes Associated with Conventional Salvage Therapy in Patients with Refractory or Relapsed AML and IDH1/IDH2 Mutations

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Overall Survival Benefit in Relapsed and Refractory B-Cell ALL Patients Receiving Inotuzumab Ozogamicin

EHA 2016, EHA 2016 – Leukemia, EHA

Conference Correspondent — July 1, 2016

Page 20 of 44

17
18
19
20
21
22
23